Erro M E, Arrondo P, Gastón I, Clavero P, de Gordoa J Sánchez Ruiz, Martí Andrés G, Valentí R, Delfrade J, Vicente E
Department of Neurology, Hospital Universitario de Navarra, C/Irunlarrea 3, 31008, Pamplona, Navarra, Spain.
Epigenetic Group, NavarraBiomed, Pamplona, Spain.
J Neurol. 2024 Oct;271(10):6647-6654. doi: 10.1007/s00415-024-12561-4. Epub 2024 Aug 13.
Epidemiological studies on multisystem atrophy (MSA) are scarce. Our aim has been to analyse 10-year incidence, point prevalence, survival, and the time to diagnosis of MSA in Navarre, a northern Spanish region.
This is a population-based observational retrospective study, from 2012 to 2021, which covered the population of Navarre (followed until 31 December 2021). Data from various sources of health information were reviewed in order to identify all potential diagnoses of MSA, that were validated from medical records. Patients were included if they fulfilled the new Movement Disorder Society criteria.
We observed a crude average annual incidence rate (IR) of 0.49/100,000 person-years, with the highest occurring in the age group of 60-69 years. No significant IR differences by sex or subtype were observed. Point prevalence in December 2021 was 2.43/100,000 inhabitants. Joinpoint analysis for global incidence and prevalence experienced stable annual rates during the whole period, showing an upward trend for prevalence without a statistically significant slop. The median age at symptom onset was 65 years (range 47-76). The median time to diagnosis was 36 months, without statistically significant differences between sex, age at diagnosis or subtypes. Median time of survival from clinical onset was 7 years. Age of onset above 70 years and autonomic onset were associated with reduced survival.
This is the first population-based epidemiological study on MSA in Spain. It provides detailed incidence and prevalence data for MSA that may be useful for appropriate management of health resources.
关于多系统萎缩（MSA）的流行病学研究较少。我们的目的是分析西班牙北部纳瓦拉地区MSA的10年发病率、时点患病率、生存率及诊断时间。
这是一项基于人群的观察性回顾性研究，研究时间为2012年至2021年，涵盖纳瓦拉地区人口（随访至2021年12月31日）。回顾了各种健康信息来源的数据，以识别所有潜在的MSA诊断，并从医疗记录中进行验证。符合新的运动障碍协会标准的患者被纳入研究。
我们观察到粗年均发病率为0.49/100,000人年，最高发病率出现在60 - 69岁年龄组。未观察到性别或亚型之间的发病率有显著差异。2021年12月的时点患病率为2.43/100,000居民。全球发病率和患病率的Joinpoint分析显示，在整个研究期间年发病率稳定，患病率呈上升趋势，但斜率无统计学意义。症状出现的中位年龄为65岁（范围47 - 76岁）。诊断的中位时间为36个月，性别、诊断时年龄或亚型之间无统计学显著差异。从临床发病开始的中位生存时间为7年。发病年龄在70岁以上和自主神经症状起病与生存率降低有关。
这是西班牙第一项基于人群的MSA流行病学研究。它提供了MSA详细的发病率和患病率数据，可能有助于合理管理卫生资源。
